Therefore, we established an ‘anti-/pro-tumor model’ defined by an established host-related ‘anti-tumor’ factor (CD8+ T lymphocytes) and ‘pro-tumor’ factors (CSCs and TB), and evaluated the prognostic significance of the ‘anti-/pro-tumor model’ in patients with PDAC. The gene discussed is CD8A; the disease is neoplasm.